July 17 (Reuters) - Danish drugmaker Novo Nordisk said on Friday that India's drug regulator has approved its obesity drug ...

MEXICO: TANZANIA is pursuing a comprehensive strategy to tackle malnutrition while addressing the growing burden of ...

Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A Mayo Clinic ...

Novo Nordisk's Wegovy receives CDSCO approval as India's first GLP-1 treatment for fatty liver disease, addressing rising ...

New research published in The American Journal of Preventive Medicine and presented at this year's International Congress on ...

A review suggests that although obesity medications, such as GLP-1 drugs, can result in substantial weight loss, many obesity ...

Novo Nordisk said about two in three people in India have fatty liver disease, which offers immense potential for the ...

A decade ago, in March 2016, Prime Minister Narendra Modi first mentioned obesity in his 18th Mann Ki Baat address. Since ...

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development ...

The CDSCO has approved a new indication for Wegovy (semaglutide injection 2.4 mg) for treatment of noncirrhotic metabolic ...

Dr. Mehmet Oz backs GLP-1 weight loss medication but stresses that diet and exercise remain essential, calling obesity the ...

It might seem like semantics. But whether a health condition qualifies as a disease can have a huge impact on patient experiences and treatment options.